Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TBHC
2501
DELISTED
The Brand House Collective
TBHC
| $1.33M | ﹤0.01% |
1,076,700
+39,400
| +4% | +$52.7K |
|
2502
Pinnacle Financial Partners Inc
PNFP
$16.3B
| $1.33M | ﹤0.01% |
20,800
-39,657
| -66% | -$2.39M |
|
2503
Gevo
GEVO
$413M
| $1.33M | ﹤0.01% |
575,294
+41,900
| +8% | +$107K |
|
2504
TORM
TRMD
$3.08B
| $1.33M | ﹤0.01% |
+118,746
| New | +$1.13M |
|
|
AIOS
2505
AIOS Tech
AIOS
$39.8M
| $1.33M | ﹤0.01% |
1,145
+460
| +67% | +$460K |
|
|
BSQR
2506
DELISTED
BSQUARE Corporation
BSQR
| $1.33M | ﹤0.01% |
954,023
+18,344
| +2% | +$22.5K |
|
|
AVX
2507
DELISTED
AVX Corporation
AVX
| $1.32M | ﹤0.01% |
64,600
-96,300
| -60% | -$1.66M |
|
|
DHC
2508
Diversified Healthcare Trust
DHC
$2.02B
| $1.32M | ﹤0.01% |
156,400
-664,806
| -81% | -$5.6M |
|
|
AT
2509
DELISTED
Atlantic Power Corporation
AT
| $1.31M | ﹤0.01% |
563,835
+29,600
| +6% | +$70.1K |
|
|
MMX
2510
DELISTED
Maverix Metals Inc. Common Shares
MMX
| $1.31M | ﹤0.01% |
+256,600
| New | +$1.11M |
|
2511
Ceco Environmental
CECO
$4.62B
| $1.3M | ﹤0.01% |
170,214
-59,469
| -26% | -$445K |
|
2512
FlexShares Global Upstream Natural Resources Index Fund
GUNR
$7.05B
| $1.3M | ﹤0.01% |
+38,904
| New | +$1.24M |
|
|
DZSI
2513
DELISTED
DZS Inc. Common Stock
DZSI
| $1.29M | ﹤0.01% |
146,097
-13,990
| -9% | -$110K |
|
2514
Consumer Portfolio Services
CPSS
$207M
| $1.29M | ﹤0.01% |
382,586
+11,678
| +3% | +$39.5K |
|
|
TBRG
2515
DELISTED
TruBridge
TBRG
| $1.28M | ﹤0.01% |
48,676
+19,000
| +64% | +$474K |
|
2516
Flanigan's Enterprises
BDL
$87.8M
| $1.28M | ﹤0.01% |
57,800
+1,900
| +3% | +$42.8K |
|
2517
iShares MSCI Switzerland ETF
EWL
$2.21B
| $1.28M | ﹤0.01% |
+31,500
| New | +$1.22M |
|
2518
Tantech Holdings
TANH
$5.55M
| $1.27M | ﹤0.01% |
73
+25
| +52% | +$408K |
|
|
CXDC
2519
DELISTED
China XD Plastics Company Limited
CXDC
| $1.27M | ﹤0.01% |
711,080
+65,100
| +10% | +$129K |
|
|
MTL
2520
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
| $1.27M | ﹤0.01% |
618,169
+103,753
| +20% | +$194K |
|
2521
Cedar Fair
FUN
$1.69B
| $1.27M | ﹤0.01% |
22,938
+997
| +5% | +$56.1K |
|
2522
iShares S&P 100 ETF
OEF
$20.5B
| $1.27M | ﹤0.01% |
+8,800
| New | +$1.21M |
|
|
SMTX
2523
DELISTED
SMTC Corporation
SMTX
| $1.27M | ﹤0.01% |
373,410
-25,200
| -6% | -$68.1K |
|
|
FOLD
2524
DELISTED
Amicus Therapeutics
FOLD
| $1.26M | ﹤0.01% |
129,854
-1,340,946
| -91% | -$12.3M |
|
2525
MediWound
MDWD
$174M
| $1.26M | ﹤0.01% |
58,201
+17,215
| +42% | +$357K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.